Beyond The Fine Print: OPDP's 2026 DTC Letters Redefine Net Impression

By Alan Minsk, Laura LaBrie, and Grace Gluck

The U.S. Food and Drug Administration’s Office of Prescription Drug Promotion's (OPDP’s) 2026 untitled letters do more than identify a handful of promotional missteps. Read together with the agency’s concentrated enforcement activity in September 2025, they suggest that OPDP may be placing greater practical emphasis on consumer takeaway and net-impression analysis when evaluating direct-to-consumer promotion.

For life sciences companies, the issue is no longer limited to isolated wording problems in television commercials or social media posts. The emerging lesson from recent enforcement activity is that OPDP appears increasingly focused on how consumers experience promotional communications as a whole, particularly where benefit-forward creative execution may overshadow, dilute, or minimize risk information.

This is not a new legal or regulatory standard. FDA has long evaluated prescription drug promotion under principles prohibiting false or misleading representations and the omission of material facts. What may be changing is the intensity of enforcement of those longstanding principles as applied to modern advertising formats and consumer engagement strategies.

From A 2025 Enforcement Surge To A 2026 Pattern

As reflected in FDA’s OPDP untitled letters page, there is a notable concentration of enforcement activity on September 9, 2025, followed by additional letters through late 2025 until today. While it would be premature to characterize this activity as a formal policy shift, the pattern suggests sustained regulatory attention to DTC promotion, largely echoing existing enforcement themes applied to increasingly sophisticated advertising formats.

Viewed through that lens, the 2025–2026 letters may represent less of a doctrinal change and more of an operational intensification (although Secretary of Health and Human Services Robert Kennedy Jr. and some members of Congress have more closely scrutinized DTC promotion). Sponsors that continue to rely on dense disclosures, rapidly delivered major statements, or risk information relegated to secondary locations may find that those approaches receive closer attention when evaluated through the lens of overall consumer understanding.

What The 2026 Letters Actually Show

The 2026 untitled letters contain recurring themes, including omission of material risk information, minimization of safety concerns, broad efficacy messaging, and failure to communicate important limitations on use. The larger lesson, however, is that OPDP appears increasingly interested in how these elements interact to create an overall consumer takeaway.

In several recent letters (whether notices of violation or warning letters), the agency focused not only on whether a risk was technically disclosed but on whether the presentation of the advertisement effectively diminished the significance of that disclosure. Benefit claims, emotional storytelling, visual imagery, music, pacing, narration, and sequencing can all influence how consumers perceive a product’s safety and effectiveness.

The breadth of sponsors and products involved in recent enforcement activity is also noteworthy. The letters span multiple therapeutic areas and promotional formats, suggesting that OPDP’s concerns are not limited to any particular disease state or category of sponsor. This reflects broader concerns regarding DTC advertising that prioritizes simplicity and emotional engagement without adequately preserving fair balance.

Net Impression As The Practical Standard

Net impression has long been a cornerstone of FDA promotional review. The concept derives from longstanding principles under the Federal Food, Drug, and Cosmetic Act, including FDA’s authority to consider not only express statements but also the overall message conveyed to consumers through representations and omissions.

Sponsors should assume OPDP will closely evaluate at least four overlapping dimensions of DTC communications:

• The prominence of benefit claims.
• The accessibility, timing, and clarity of risk information.
• The communication of important indication limitations, such as patient populations, lines of therapy, biomarker requirements, or co-therapy conditions.
• The extent to which visuals, pacing, and user-interface design reinforce or undermine risk disclosures.

This approach effectively narrows the historical divide between creative development and regulatory review. In modern DTC campaigns, visual design, user experience, scene selection, voiceover cadence, and platform-specific presentation may all influence whether a communication is considered misleading.

Illustrative Enforcement Themes

Although each letter turns on its specific facts, recent matters provide useful examples of the types of concerns drawing OPDP attention.

In several letters — including, for example, the Feb. 5 Novo Nordisk one — OPDP objected to promotional presentations that emphasized positive treatment outcomes while providing insufficient context regarding material risks. The agency also focuses on communications that fail to adequately convey important limitations on use provided in the product label, thereby creating an impression that the product was appropriate for broader patient populations than supported by the approved labeling. In addition, recent enforcement actions demonstrate that OPDP’s concerns can arise not only from explicit claims but also from implication, juxtaposition, narrative framing, and selective omission of context. The lesson for sponsors is that consumer takeaway is often more important than individual component parts.

The Broader Policy Narrative

The significance of these letters extends beyond the specific campaigns involved. DTC advertising has become an increasingly visible policy issue as promotional content expands across streaming television, social media, websites, patient-support platforms, and other digital channels. Some commentators have questioned whether traditional regulatory requirements such as fair balance and adequate provision remain well suited to modern advertising environments characterized by short-form content, fragmented attention spans, and platform-specific user experiences. At the same time, others have argued that aggressive enforcement positions risk stretching established principles governing commercial speech.

Whether one views recent enforcement activity as a necessary modernization of oversight or a more expansive interpretation of promotional authority, the practical reality remains the same: Promotional teams may need to revisit their risk tolerance and tighten their marketing approach.

The recent letters suggest that the agency may be increasingly focused on what ordinary consumers are likely to understand from an advertisement in context rather than whether a sponsor can point to disclosure language somewhere within the promotional piece. What previously may have been placed in a smaller-font disclaimer might now require greater prominence.

Why This Matters For Commercial Strategy

DTC advertising remains a major investment for many pharmaceutical and biotechnology companies. Further, if OPDP identifies an issue with a core claim, changes must be carried through to each promotional piece containing the violative messaging. Enacting such changes across a body of promotional pieces can be extremely costly and time-consuming.

In competitive therapeutic categories, commercial success often depends on awareness, differentiation, and patient activation. If regulators are placing greater emphasis on audience takeaway and net impression, companies may need to rethink some traditional assumptions regarding campaign development. This is particularly relevant in three settings:

1. Broad consumer launches. Sponsors launching products into large consumer markets frequently rely on quality-of-life and lifestyle-oriented narratives emphasizing confidence, independence, or normalcy. While these themes can be commercially effective, they carry great risk and often exceed the clinical evidence supporting the product or distract consumers from material safety considerations.
2. Specialty and oncology products. Sponsors promoting highly specialized therapies may face heightened scrutiny when indication limitations are not integrated into the core promotional narrative. Biomarker requirements, prior-treatment criteria, line-of-therapy restrictions, and co-therapy obligations are often central elements of approved labeling and may need to receive greater prominence in consumer-facing communications.
3. Competitive markets. Competitive environments create natural incentives to differentiate products. However, comparative claims must be supported by head-to-head data. Recent enforcement activity demonstrates that superiority messages can be communicated implicitly through narrative framing and context, even when no express comparative claim is made. Sponsors should therefore evaluate not only what advertisements say but also what consumers are likely to infer.

The Digital Content Challenge

Today’s campaigns often generate large volumes of promotional assets across websites, streaming platforms, social media channels, search engines, email communications, and modular content libraries. As content volume increases, so does the risk that important qualifiers, risk disclosures, or indication limitations will be applied inconsistently across executions.

This challenge exists regardless of whether future regulatory oversight incorporates advanced technology-assisted review methods. The practical concern for sponsors is straightforward: Larger promotional ecosystems create more opportunities for variation, inconsistency, and drift from approved messaging. As a result, many organizations are beginning to view promotional compliance as an operational capability rather than a series of individual legal reviews. Much like quality systems and pharmacovigilance programs, effective promotional governance increasingly depends on repeatable processes, documentation, oversight, and consistency across channels.

Proposed Areas For Change

The emerging enforcement trend points toward practical recalibration rather than wholesale reinvention. When developing or reviewing new campaigns for OPDP compliance, we recommend an extra focus on the following areas:

Build campaigns from approved product labeling. Rather than allowing creative concepts to develop independently before regulatory review, sponsors should establish core messaging frameworks around approved indications, label-supported benefits, material risks, and critical limitations on use. This approach helps reduce the likelihood that late-stage review will expose structural issues within the campaign concept itself.

Treat risk communication as a design function. Risk information is not simply text that must be inserted into promotional materials. It must successfully compete for audience attention. Therefore, sponsors should provide agencies with specific direction regarding pacing, visual presentation, font size, audio delivery, and avoidance of distracting imagery during risk discussions.

Review for consumer takeaway, not merely technical accuracy. Promotional review often focuses on whether individual statements can be substantiated, but companies should ask what consumers are likely to conclude from the materials. Consumer research, audience testing, audio-only reviews, and structured takeaway assessments can provide valuable insight into whether the communication is balanced and understandable.

Strengthen modular content controls. Modern campaigns frequently generate dozens or hundreds of derivative assets. Organizations should implement systems that help ensure all messaging remains consistent as content is adapted across channels and formats.

Look Through The Consumer Lens For Net Impression

The 2025–2026 OPDP letters are best understood not as evidence of new requirements but as a potential signal regarding how FDA is applying longstanding promotional standards in a modern advertising environment. OPDP appears increasingly focused on consumer understanding, overall takeaway, and the practical realities of how consumers absorb promotional messages. Benefit claims, disclosures, visuals, sequencing, and platform design are no longer easily separated for compliance purposes as they collectively shape the net impression conveyed to patients.

For life sciences companies, the lesson extends beyond legal or regulatory risk. The challenge is operational and strategic. As promotional ecosystems become more complex and consumer-facing communications continue to expand across channels, organizations that integrate compliance considerations earlier in campaign development may be better positioned to preserve both regulatory credibility and commercial effectiveness.

In short, the recent letters suggest that traditional disclosure practices may provide limited protection when the overall consumer takeaway remains misleading. Whether viewed as an enforcement trend or an evolving standard, net impression is increasingly becoming the lens through which DTC promotion is evaluated.

About The Authors:

Alan Minsk, a partner at law firm Arnall Golden Gregory, advises pharmaceutical, biologic, medical device, cosmetic, and food companies on FDA-related legal and regulatory matters. He also works with life science companies and venture capital firms on regulatory diligence matters; drafts and reviews agreements relating to clinical trials, quality, and contract manufacturing; and conducts in-house training on FDA and fraud and abuse topics. Alan can be reached at alan.minsk@agg.com.

Laura LaBrie, an associate at Arnall Golden Gregory, handles a variety of regulatory, compliance, and transactional matters within the healthcare industry with a focus on FDA-related products and industry. She can be reached at laura.labrie@agg.com.

Grace Gluck is an associate at Arnall Golden Gregory, where she provides transactional and regulatory counsel for a variety of clients across the healthcare industry. She can be reached at grace.gluck@agg.com.